Irbesartan Alter (Irbesartan)

• Irbesartan is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.
• Hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular risk profile.
• Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.
• Heart failure: decreases ventricular workload and may improve symptoms in patients with left‑ventricular dysfunction.

• Irbesartan selectively antagonizes angiotensin II type 1 (AT1) receptors on vascular smooth‑muscle cells, adrenal cortex, and renal tubular cells. By blocking AT1 activation, it prevents vasoconstriction, aldosterone secretion, and sympathetic stimulation, leading to vasodilation, reduced sodium‑water retention, and lowered blood pressure. The inhibition also reduces pathological remodeling of the cardiovascular system and improves renal hemodynamics, contributing to its therapeutic benefits in hypertension, diabetic kidney disease, and heart failure.

Irbesartan may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

• Dizziness: light‑headedness, especially after the first dose, may resolve with continued therapy.
• Headache: mild to moderate head pain that can occur during treatment.
• Fatigue: feeling of tiredness or reduced energy levels.
• Hyperkalemia: mild elevation of blood potassium levels, often asymptomatic.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or airway requiring emergency care.
• Renal impairment: sudden decrease in kidney function, indicated by rising creatinine.
• Hepatic injury: signs of liver dysfunction such as jaundice or elevated transaminases.

• When prescribing Irbesartan, several precautions should be observed to ensure patient safety.
• Blood pressure monitoring: check regularly to ensure therapeutic response and avoid hypotension.
• Renal function: assess serum creatinine and eGFR before initiation and periodically during treatment.
• Electrolytes: monitor potassium levels, particularly in patients with renal impairment or on potassium‑sparing diuretics.
• Pregnancy: contraindicated in pregnancy (Category D); discontinue if pregnancy is confirmed.
• Drug interactions: review concomitant medications for potential additive hypotensive or hyperkalemic effects.
• Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight in the original packaging.

Irbesartan can interact with several medicines, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: may cause dangerous hyperkalemia.
• ACE inhibitors or other ARBs: additive risk of hypotension and renal dysfunction.
• Aliskiren (in diabetics): increased risk of renal impairment, hyperkalemia, and hypotension.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate antihypertensive effect and affect renal function.
• Spironolactone: can increase potassium levels, requiring monitoring.
• Lithium: may increase serum lithium concentrations, necessitating level checks.